Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Collegium Pharmaceutical, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

STOUGHTON, MASS., NOV. 12, 2025 (GLOBE NEWSWIRE) -- COLLEGIUM PHARMACEUTICAL, INC.(NASDAQ: COLL) TODAY ANNOUNCED THAT ITS MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES: JEFFERIES LONDON HEALTHCARE CONFERENCE PRESENTATION DATE AND TIME: WEDNESDAY, NOVEMBER 19, 2025, AT 8:00 A.M.

COLLEGIUM TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

 GENERATED RECORD QUARTERLY NET REVENUE OF $209.4 MILLION, UP 31% YEAR-OVER-YEAR   GENERATED RECORD QUARTERLY JORNAY PM  NET REVENUE OF$41.8 MILLION; GREW PRESCRIPTIONS BY 20% YEAR-OVER-YEAR   GENERATED RECORD QUARTERLY PAIN PORTFOLIO NET REVENUE OF$167.6 MILLION, UP 11% YEAR-OVER-YEAR, WITH ALL THREE CORE PRODUCTS GROWING YEAR-OVER-YEAR   RAISED FULL-YEAR 2025 NET REVENUE GUIDANCE TO BE IN THE RANGE OF $775 TO $785 MILLION AND ADJUSTED EBITDA GUIDANCE IN THE RANGE OF $460 TO $470 MILLION   ENDED Q3'25 WITH CASH,CASH EQUIVALENTS AND MARKETABLE SECURITIESOF$285.9 MILLION   CONFERENCE CALL SCHEDULED FOR TODAY AT 8:00 A.M. ET  STOUGHTON, MASS.

COLLEGIUM REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS; RAISES 2025 GUIDANCE

MONTREAL, OCT. 30, 2025 (GLOBE NEWSWIRE) -- KNIGHT THERAPEUTICS INC. (TSX: GUD) ("KNIGHT"), A PAN-AMERICAN (EX-USA) SPECIALTY PHARMACEUTICAL COMPANY, ANNOUNCED TODAY THE LAUNCH OF JORNAY PM (METHYLPHENIDATE HCI EXTENDED-RELEASE CAPSULES) IN CANADA. JORNAY PM IS AN EXTENDED-RELEASE FORMULATION OF METHYLPHENIDATE, A STIMULANT MEDICATION FOR THE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN 6-12 YEARS OF AGE.1

KNIGHT THERAPEUTICS ANNOUNCES LAUNCH OF JORNAY PM IN CANADA

STOUGHTON, MASS., OCT. 23, 2025 (GLOBE NEWSWIRE) -- COLLEGIUM PHARMACEUTICAL, INC.(NASDAQ: COLL) TODAY ANNOUNCED THAT IT WILL REPORT THIRD QUARTER 2025 FINANCIAL RESULTS BEFORE THE MARKET OPENS ONTHURSDAY, NOVEMBER 6, 2025.

COLLEGIUM TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS ON NOVEMBER 6, 2025

STOUGHTON, MASS., OCT. 22, 2025 (GLOBE NEWSWIRE) -- COLLEGIUM PHARMACEUTICAL, INC. (NASDAQ: COLL) TODAY ANNOUNCED IT WILL HAVE POSTER PRESENTATIONS HIGHLIGHTING REAL-WORLD DATA FROM ITS DIFFERENTIATED NEUROPSYCHIATRY PRODUCT, JORNAY PM, (METHYLPHENIDATE HCL), A CENTRAL NERVOUS SYSTEM (CNS) STIMULANT FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEOPLE 6 YEARS OF AGE AND OLDER AT THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY (AACAP) AND NEUROSCIENCE EDUCATION INSTITUTE (NEI) CONFERENCES.

COLLEGIUM ANNOUNCES POSTER PRESENTATIONS AT THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY AND NEUROSCIENCE EDUCATION INSTITUTE CONFERENCES

STOUGHTON, MASS., OCT. 13, 2025 (GLOBE NEWSWIRE) -- COLLEGIUM PHARMACEUTICAL, INC. (NASDAQ: COLL) TODAY ANNOUNCED THAT ITS MANAGEMENT TEAM WILL RING THE NASDAQ OPENING BELL ON OCTOBER 14, 2025 AT 9:30 A.M.

COLLEGIUM TO CELEBRATE 10-YEAR ANNIVERSARY WITH NASDAQ OPENING BELL RINGING

STOUGHTON, MASS., AUG. 28, 2025 (GLOBE NEWSWIRE) -- COLLEGIUM PHARMACEUTICAL, INC.(NASDAQ: COLL) TODAY ANNOUNCED THAT ITS MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES: 2025 WELLS FARGO HEALTHCARE CONFERENCE THURSDAY, SEPTEMBER 4, 2025BOSTON, MA MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE FIRESIDE CHAT DATE AND TIME: MONDAY, SEPTEMBER 8, 2025 AT 2:35 P.M.

STOUGHTON, MASS., AUG. 25, 2025 (GLOBE NEWSWIRE) -- COLLEGIUM PHARMACEUTICAL, INC. (NASDAQ: COLL) TODAY ANNOUNCED IT WILL PRESENT NINE POSTERS SHOWCASING REAL-WORLD DATA FROM ITS DIFFERENTIATED PAIN PORTFOLIO AT PAINWEEK 2025, TAKING PLACE IN LAS VEGAS, NV, SEPTEMBER 2-5, 2025.

COLLEGIUM TO PRESENT NINE REAL-WORLD DATA POSTERS AT PAINWEEK 2025 ANNUAL MEETING

 GENERATED RECORD QUARTERLY NET REVENUE OF $188.0 MILLION, UP 29% YEAR-OVER-YEAR   GENERATED RECORD QUARTERLY JORNAY PM  NET REVENUE OF$32.6 MILLION AND GREW PRESCRIPTIONS BY 23% YEAR-OVER-YEAR   GENERATED NET REVENUE OF$155.4 MILLIONFROM THE PAIN PORTFOLIO, UP 7% YEAR-OVER-YEAR WITH ALL THREE CORE PRODUCTS RECORDING REVENUE GROWTH IN THE QUARTER   RAISED FULL-YEAR 2025 NET REVENUE GUIDANCE TO BE IN THE RANGE OF $745 TO $760 MILLION AND ADJUSTED EBITDA GUIDANCE IN THE RANGE OF $440 TO $455 MILLION   ENDED Q2'25 WITH CASH,CASH EQUIVALENTS AND MARKETABLE SECURITIESOF$222.2 MILLION   BOARD OF DIRECTORS AUTHORIZED $150 MILLION SHARE REPURCHASE PROGRAM   CONFERENCE CALL SCHEDULED FOR TODAY AT 8:00 A.M. ET  STOUGHTON, MASS.

COLLEGIUM REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS; RAISES 2025 OUTLOOK

STOUGHTON, MASS., JULY 24, 2025 (GLOBE NEWSWIRE) -- COLLEGIUM PHARMACEUTICAL, INC.(NASDAQ: COLL) TODAY ANNOUNCED THAT IT WILL REPORT SECOND QUARTER 2025 FINANCIAL RESULTS BEFORE THE MARKET OPENS ONTHURSDAY, AUGUST 7, 2025. FOLLOWING THE RELEASE OF THE FINANCIALS, THE COMPANY WILL HOST A LIVE CONFERENCE CALL AND WEBCAST AT8:00 A.M. ET.

Collegium Pharmaceutical, Inc.

COLL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Collegium Pharmaceutical, Inc.

COLL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

COLL